Home Ventilation / CPAP in Germany March 2019
SKU:
$2,490.00
$2,490.00
per item
Description
In Germany, there are around 2.1 million people diagnosed with sleep apnea. The dark figure, however, is much higher: 80% of all patients know nothing about their illness. Patients with a sleep apnea are provided with a CPAP, with some 200,000 primary care units and 700,000 follow-up supplies per year using a CPAP device.
The number of patients who are supplied with home ventilation is also steadily increasing. Around one third of the patients are invasive and two-thirds non-invasive. A trigger for the rising number is above all the introduction of the DRGs, whereby the lying time in the hospital is shortened. At the same time, however, the professional offers of extraclinical intensive care and respiratory care are also increasing.
The Qnidos Deutsche Health Intelligence Study "Respiratory Therapy / CPAP" provides executives of manufacturers and service providers with a comprehensive insight into the current and future market conditions of the outpatient respiratory market. The focus of the market investigation is on the detailed presentation of the competitive situation of manufacturers and service providers and the reimbursement situation of health insurance funds.
In addition, the report provides an overview of the disease patterns relevant to this form of care and their distribution, as well as the number of patients who are acutely affected by this form of care.
In addition to a detailed growth forecast for the next three years, the study answers the following questions on ventilation therapy / CPAP:
What are CPAP and respiratory therapies?
How many people suffer from a COPD?
What forms of sleep apnea are there?
What is the reimbursement market for CPAP and home breathing?
How will price pressure in the future affect the cost carriers?
The number of patients who are supplied with home ventilation is also steadily increasing. Around one third of the patients are invasive and two-thirds non-invasive. A trigger for the rising number is above all the introduction of the DRGs, whereby the lying time in the hospital is shortened. At the same time, however, the professional offers of extraclinical intensive care and respiratory care are also increasing.
The Qnidos Deutsche Health Intelligence Study "Respiratory Therapy / CPAP" provides executives of manufacturers and service providers with a comprehensive insight into the current and future market conditions of the outpatient respiratory market. The focus of the market investigation is on the detailed presentation of the competitive situation of manufacturers and service providers and the reimbursement situation of health insurance funds.
In addition, the report provides an overview of the disease patterns relevant to this form of care and their distribution, as well as the number of patients who are acutely affected by this form of care.
In addition to a detailed growth forecast for the next three years, the study answers the following questions on ventilation therapy / CPAP:
What are CPAP and respiratory therapies?
How many people suffer from a COPD?
What forms of sleep apnea are there?
What is the reimbursement market for CPAP and home breathing?
How will price pressure in the future affect the cost carriers?
